# EDGAR Filing Document

**Accession Number:** 0001695076
**File Stem:** 0001012975-26-000173
**Filing Date:** 2026-2
**Character Count:** 31666
**Document Hash:** 13055f943f03922fb183cbdd0fe2b5e4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001012975-26-000173.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001012975-26-000173

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bolt Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001641281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472804636
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92160
- **FILM NUMBER:** 26644779

**BUSINESS ADDRESS:**
- **STREET 1:** 900 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 650-665-9295

**MAIL ADDRESS:**
- **STREET 1:** 900 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bolt Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20150504
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pivotal bioVenture Partners Fund I, L.P.
- **CENTRAL INDEX KEY:** 0001695076

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 501 SECOND STREET, SUITE 200
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107
- **BUSINESS PHONE:** (345) 949 1040

**MAIL ADDRESS:**
- **STREET 1:** 501 SECOND STREET, SUITE 200
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pivotal Venture Partners Fund I, L.P.
- **DATE OF NAME CHANGE:** 20170118

## Ex-99.A

<u>Schedule A</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Fund | &nbsp;&nbsp;Date | &nbsp;&nbsp;Transaction | &nbsp;&nbsp;Number of shares | &nbsp;&nbsp;Price |
| &nbsp;&nbsp;Pivotal bioVenture Partners Fund I, L.P. | &nbsp;&nbsp;01/28/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;3257 | &nbsp;&nbsp;$6.8348 |
| &nbsp;&nbsp;NFLS Beta Limited | &nbsp;&nbsp;01/28/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;1343 | &nbsp;&nbsp;$6.8502 |
| &nbsp;&nbsp;Pivotal bioVenture Partners Fund I, L.P. | &nbsp;&nbsp;01/29/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;2612 | &nbsp;&nbsp;$6.4524 |
| &nbsp;&nbsp;NFLS Beta Limited | &nbsp;&nbsp;01/29/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;1488 | &nbsp;&nbsp;$6.4524 |
| &nbsp;&nbsp;Pivotal bioVenture Partners Fund I, L.P. | &nbsp;&nbsp;01/30/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;1657 | &nbsp;&nbsp;$6.1325 |
| &nbsp;&nbsp;NFLS Beta Limited | &nbsp;&nbsp;01/30/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;943 | &nbsp;&nbsp;$6.1325 |
| &nbsp;&nbsp;Pivotal bioVenture Partners Fund I, L.P. | &nbsp;&nbsp;02/02/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;1402 | &nbsp;&nbsp;$6.0495 |
| &nbsp;&nbsp;NFLS Beta Limited | &nbsp;&nbsp;02/02/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;798 | &nbsp;&nbsp;$6.0495 |
| &nbsp;&nbsp;Pivotal bioVenture Partners Fund I, L.P. | &nbsp;&nbsp;02/03/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;319 | &nbsp;&nbsp;$6.0141 |
| &nbsp;&nbsp;NFLS Beta Limited | &nbsp;&nbsp;02/03/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;182 | &nbsp;&nbsp;$6.0141 |
| &nbsp;&nbsp;Pivotal bioVenture Partners Fund I, L.P. | &nbsp;&nbsp;02/05/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;2867 | &nbsp;&nbsp;$5.7272 |
| &nbsp;&nbsp;NFLS Beta Limited | &nbsp;&nbsp;02/05/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;1633 | &nbsp;&nbsp;$5.7272 |
| &nbsp;&nbsp;Pivotal bioVenture Partners Fund I, L.P. | &nbsp;&nbsp;02/06/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;1720 | &nbsp;&nbsp;$5.58 |
| &nbsp;&nbsp;NFLS Beta Limited | &nbsp;&nbsp;02/06/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;980 | &nbsp;&nbsp;$5.58 |
| &nbsp;&nbsp;Pivotal bioVenture Partners Fund I, L.P. | &nbsp;&nbsp;02/09/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;510 | &nbsp;&nbsp;$5.5139 |
| &nbsp;&nbsp;NFLS Beta Limited | &nbsp;&nbsp;02/09/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;290 | &nbsp;&nbsp;$5.5139 |
| &nbsp;&nbsp;Pivotal bioVenture Partners Fund I, L.P. | &nbsp;&nbsp;02/12/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;510 | &nbsp;&nbsp;$4.9606 |
| &nbsp;&nbsp;NFLS Beta Limited | &nbsp;&nbsp;02/12/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;290 | &nbsp;&nbsp;$4.9606 |
| &nbsp;&nbsp;Pivotal bioVenture Partners Fund I, L.P. | &nbsp;&nbsp;02/13/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;1274 | &nbsp;&nbsp;$5.0073 |
| &nbsp;&nbsp;NFLS Beta Limited | &nbsp;&nbsp;02/13/2026 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;726 | &nbsp;&nbsp;$5.0073 |

---

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Bolt Biotherapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, $0.00001 par value**

*(Title of Class of Securities)*

**097702203**

*(CUSIP Number)*

**Robert Hopfner**<br>Pivotal bioVenture Partners Fund I UGP<br>501 2nd Street, Suite 200<br>San Francisco CA 94107<br>(415) 697-1002

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**02/05/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Nan Fung Group Holdings Limited** | Name of reporting person<br>**Nan Fung Group Holdings Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**128119.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**128119.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**128119.00** | Aggregate amount beneficially owned by each reporting person<br>**128119.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.7%** | Percent of class represented by amount in Row (11)<br>**6.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**NF Investment Holdings Limited** | Name of reporting person<br>**NF Investment Holdings Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**128119.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**128119.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**128119.00** | Aggregate amount beneficially owned by each reporting person<br>**128119.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.7%** | Percent of class represented by amount in Row (11)<br>**6.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pivotal bioVenture Partners Fund I, L.P.** | Name of reporting person<br>**Pivotal bioVenture Partners Fund I, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**78445.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**78445.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**78445.00** | Aggregate amount beneficially owned by each reporting person<br>**78445.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.1%** | Percent of class represented by amount in Row (11)<br>**4.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pivotal bioVenture Partners Fund I G.P., L.P.** | Name of reporting person<br>**Pivotal bioVenture Partners Fund I G.P., L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**78445.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**78445.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**78445.00** | Aggregate amount beneficially owned by each reporting person<br>**78445.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.1%** | Percent of class represented by amount in Row (11)<br>**4.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pivotal bioVenture Partners Fund I U.G.P. Ltd.** | Name of reporting person<br>**Pivotal bioVenture Partners Fund I U.G.P. Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**78445.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**78445.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**78445.00** | Aggregate amount beneficially owned by each reporting person<br>**78445.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.1%** | Percent of class represented by amount in Row (11)<br>**4.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pivotal Partners Ltd** | Name of reporting person<br>**Pivotal Partners Ltd** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**78445.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**78445.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**78445.00** | Aggregate amount beneficially owned by each reporting person<br>**78445.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.1%** | Percent of class represented by amount in Row (11)<br>**4.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pivotal Life Sciences Holdings Limited** | Name of reporting person<br>**Pivotal Life Sciences Holdings Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**78445.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**78445.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**78445.00** | Aggregate amount beneficially owned by each reporting person<br>**78445.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.1%** | Percent of class represented by amount in Row (11)<br>**4.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Nan Fung Life Sciences Holdings Limited** | Name of reporting person<br>**Nan Fung Life Sciences Holdings Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**123119.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**123119.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**123119.00** | Aggregate amount beneficially owned by each reporting person<br>**123119.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.4%** | Percent of class represented by amount in Row (11)<br>**6.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Permwell Management Limited** | Name of reporting person<br>**Permwell Management Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5000.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5000.00** | Aggregate amount beneficially owned by each reporting person<br>**5000.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.3%** | Percent of class represented by amount in Row (11)<br>**0.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**NFLS Beta Limited** | Name of reporting person<br>**NFLS Beta Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**44674.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**44674.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**44674.00** | Aggregate amount beneficially owned by each reporting person<br>**44674.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.3%** | Percent of class represented by amount in Row (11)<br>**2.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **097702203** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**NFLS Platform Holdings Limited** | Name of reporting person<br>**NFLS Platform Holdings Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**44674.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**44674.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**44674.00** | Aggregate amount beneficially owned by each reporting person<br>**44674.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.3%** | Percent of class represented by amount in Row (11)<br>**2.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.00001 par value

**(b) Name of Issuer:**
Bolt Biotherapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
900 Chesapeake Drive, Redwood City, CA, 94063

**Item 5. Interest in Securities of the Issuer**

**(a)**
Items 5(a)-(c) of the Schedule 13D are amended and restated as follows:

The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 1,919,441 outstanding shares of Common Stock, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025.

In addition, Mr. Kam Chung Leung directly owns 8,684 shares of Common Stock.

**(b)**
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

**(c)**
Except as set forth on Schedule A, which is incorporated into this Item 5(c) by reference, no Reporting Person has effected any transaction in shares of Common Stock in the past sixty days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Nan Fung Group Holdings Limited

**Signature:** /s/ Tang Chun Wai Nelson

**Name/Title:** Tang Chun Wai Nelson, Director

**Date:** 02/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** NF Investment Holdings Limited

**Signature:** /s/ Tang Chun Wai Nelson

**Name/Title:** Tang Chun Wai Nelson, Director

**Date:** 02/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pivotal bioVenture Partners Fund I, L.P.

**Signature:** By Pivotal bioVenture Partners Fund I G.P., L.P.

**Name/Title:** its General Partner

**Date:** 02/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pivotal bioVenture Partners Fund I G.P., L.P.

**Signature:** By Pivotal bioVenture Partners Fund I U.G.P., Ltd.

**Name/Title:** its General Partner

**Date:** 02/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pivotal bioVenture Partners Fund I U.G.P. Ltd.

**Signature:** /s/ Robert Hopfner

**Name/Title:** Robert Hopfner, Authorized Signatory

**Date:** 02/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pivotal Partners Ltd

**Signature:** /s/ Sun Xintong

**Name/Title:** Sun Xintong, Director

**Date:** 02/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pivotal Life Sciences Holdings Limited

**Signature:** /s/ Sun Xintong

**Name/Title:** Sun Xintong, Director

**Date:** 02/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Nan Fung Life Sciences Holdings Limited

**Signature:** /s/ Sun Xintong

**Name/Title:** Sun Xintong, Director

**Date:** 02/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Permwell Management Limited

**Signature:** /s/ Tang Chun Wai Nelson

**Name/Title:** Tang Chun Wai Nelson, Director

**Date:** 02/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** NFLS Beta Limited

**Signature:** /s/ Sun Xintong

**Name/Title:** Sun Xintong, Director

**Date:** 02/17/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** NFLS Platform Holdings Limited

**Signature:** /s/ Sun Xintong

**Name/Title:** Sun Xintong, Director

**Date:** 02/17/2026